Wolfe Research on Regeneron Pharma (REGN): 'Results were good'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. SPY
5. META
6. MSFT
7. USO
8. AMD
9. GMAB
10. ATH

Go back to Wolfe Research on Regeneron Pharma (REGN): 'Results were good'

Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis

September 8, 2022 11:29 AM EDT

Nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to placebo

There are currently no approved medicines specifically indicated to treat prurigo nodularis; regulatory submissions for Dupixent are under Priority Review in the U.S. and under review in the European Union

22 Dupixent abstracts are being presented at the EADV 2022 Congress across four dermatological diseases with underlying type 2 inflammation

TARRYTOWN, N.Y. and PARIS,... More

Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals

September 8, 2022 9:01 AM EDT

91% and 89% of diabetic macular edema (DME) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively

79% and 77% of wet age-related macular degeneration (wAMD) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively

Safety of aflibercept 8 mg consistent with the established safety profile of EYLEA® (aflibercept) Injection

TARRYTOWN, N.Y., Sept. 8, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.... More